Category: Pharmaceutical Recognition & Awards

First Human Injection Custom Lucite

Custom Lucite, featuring an embedded vaccine vial, recognizing the first human injection of SchistoShield, a vaccine treatment for the parisitic disease schistosomiasis. (22AZH160)

1 Image

Jnana-Roche Collaboration Commemorative

Lucite commemorative marking a collaboration between Jnana Therapeutics and Roche. The partnership centers on the development of small molecule drugs for the treatment of neurological diseases. (21AKL332)

2 Images
Side view of custom Lucite cube marking a partnership focused on the development of neurological treatments.

NF1 FDA Approval Commemorative

Custom crystal commemorating FDA approval of Gomekli, a treatment for the rare tumor disease ncurofibromatosis 1 (NF1). (25AZH094)

2 Images
Side view of crystal commemorative marking approval by the Food and Drug Administration (FDA) of a tumor treatment.

Financial Tombstone for Drug Licensing Agreement

Crystal financial tombstone, featuring a sandblasted map of the world, recognizing a licensing and commercialization agreement between X4 Pharmaceuticals and Norgine. The agreement centers onthe drug Mavorixafor, and encompasses Europe, New Zealand, and Australia. (25LNL023)

1 Image

Eye-Themed Crystal Deal Toy

Crystal deal toy commemorating a follow-on stock offering by Oculis. The Swiss biopharmaceutical company provides treatment for eye conditions such as diabetic macula edema and acute optic neuritis. (25AKL187)

1 Image

First-in-Human Dose Commemorative for Asthma Treatment

Custom Lucite commemorative recognizing the first-in-human dose of a treatment for inflammatory lung diseases. (22ALJ326)

1 Image

GSK License Agreement Lucite Tombstone

Logo-shaped Lucite tombstone, with a plexi bottom matched to a logo color, celebrating a licensing agreement between Arrowhead Pharmaceuticals and GlaxoSmithKline (GSK). The agreement centers on a treatment for liver disease. (22ALJ324)

1 Image

Cancer Therapy First-in-Human Lucite Commemorative

Custom Lucite, incorporating an embedded vial, celebrating the first-in-human dosing in a Phase 1 clinical trial of cancer treatment developed by biotech company Immunome. (25ALJ040)

2 Images
Back view of a custom Lucite with an embedded vial marking the first patient dosed with a cancer therapy.

Adrenal Drug FDA Approval Lucite

Custom Lucite celebrating the approval by the U.S. Food and Drug Administration (FDA) of the drug Crenessity. Crenessity was developed by Neurocrine Biosciences to treat a rare congenital adrenal condition. (25ALJ020)

1 Image